Rna Diagnostics Inc.

Founded 2010 10 employees Series A Total: $6.73M Health Care

Rna Diagnostics Inc. is a clinical stage molecular diagnostics company specializing in personalized cancer therapy management. The company's Veridapt DX™ predictive biomarker platform technology, currently in clinical trials, aims to measure early solid tumor response to neoadjuvant cancer treatment by identifying non-responsive solid tumors through the monitoring of RNA disruption in the cells. This technology has the potential to significantly impact cancer treatment by enabling physicians to make informed decisions about treatment escalation or de-escalation, or alternative strategies, as early as 5 weeks into a 6-month treatment regimen. The company has garnered significant attention through a Phase 1 study published in JNCI Cancer Spectrum, which demonstrated the strong capability of Veridapt DX with a Negative Predictive Value of over 93% in predicting therapy efficacy/outcomes during early treatment. Following this, Phase 2 trials are currently ongoing in 7 countries, adding to the company's growing body of evidence for clinical effectiveness. Rna Diagnostics Inc. has positioned itself as a potential game-changer in cancer treatment, with a specific focus on primary breast cancer management through the ongoing BREVITY clinical trial. However, the company emphasizes the broader applicability of its assay platform to any solid tumor and any cancer drug therapy, signaling a significant market potential for personalized, precision medicine. Notably, the company secured a Series A investment from MEDTEQ+ in July 2019, indicating investor confidence in the company's innovative approach to improving cancer treatment. Additionally, the company's proactive stance on collaborative trials for early assessment of treatment for solid tumor cancers underscores its commitment to advancing cancer care.

Funding Stage	Amount	Investors	Lead Investors	Date
Series A	Undisclosed	1	MEDTEQ+	26 Jul 2019
Series A	$5.00M	1	iGan Partners	09 Nov 2018
Angel Round	Undisclosed	3	Northern Ontario Angels, Ontario Centres of Excellence +1	15 Jan 2016
Angel Round	$800.00K	-		21 Sep 2015
Angel Round	$925.00K	5	Angel One Investor Network, York Angels Investors +3	27 Mar 2012

Funding Stage

Amount

Investors

Lead Investors

Date

Series A

Undisclosed

MEDTEQ+

26 Jul 2019

Series A

$5.00M

iGan Partners

09 Nov 2018

Angel Round

Undisclosed

Northern Ontario Angels, Ontario Centres of Excellence +1

15 Jan 2016

Angel Round

$800.00K

21 Sep 2015

Angel Round

$925.00K

Angel One Investor Network, York Angels Investors +3

27 Mar 2012

FAQ About Rna Diagnostics Inc.

Rna Diagnostics Inc. is a clinical stage molecular diagnostics company for personalized cancer therapy management. We are working with physicians around the globe to improve cancer treatment and the quality of life for patients, while reducing healthcare costs. Our predictive biomarker platform t...

Rna Diagnostics Inc. was founded in 2010.

Rna Diagnostics Inc. operates in Health Care.

Rna Diagnostics Inc. has approximately 10 employees.

Rna Diagnostics Inc. has completed 5 funding rounds, raising a total of $6.73M. The latest funding stage is Series A.

Top alternatives and competitors to Rna Diagnostics Inc. include BioMarker Strategies, LLC, Agendia, Biovica International AB, ACT Genomics, VitroScan. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Rna Diagnostics Inc. and BioMarker Strategies, LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Rna Diagnostics Inc.

Funding Rounds & Investors (5)

Rna Diagnostics Inc. Alternatives & Competitors

FAQ About Rna Diagnostics Inc.